PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy

Diabetologia
Paul M SchroderStanislaw M Stepkowski

Abstract

T cells play a major role in the pathogenesis of type 1 diabetes, and there is great interest in developing curative immunotherapies targeting these cells. In this study, a monoclonal antibody (mAb) targeting the T cell receptor β-chain (TCRβ) was investigated for its ability to prevent and reverse disease in mouse models of diabetes. RIP-OVA(hi) (C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ) mice adoptively transferred with ovalbumin-specific T cells (an induced model of diabetes) and NOD mice (a spontaneous model of diabetes) were used to test anti-TCRβ mAb therapy as a means of preventing and reversing type 1 diabetes. A single dose of anti-TCRβ completely prevented disease in RIP-OVA(hi) mice without inducing the release of inflammatory cytokines. Transient anti-TCRβ therapy prevented diabetes in 90% of NOD mice and reversed the disease after its onset in 73% of NOD mice. Long after the remission of type 1 diabetes, the anti-TCRβ treated mice were able to reject BALB/c skin allografts with normal kinetics while maintaining normoglycaemia. Treatment did not cause significant reductions in lymphocyte numbers in the spleen or pancreatic lymph nodes, but did result in a decreased percentage of chemokine receptor 9 (CCR9) positive, CD8(+) T...Continue Reading

References

Dec 1, 1991·Clinical and Experimental Immunology·C FerranL Chatenoud
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·L ChatenoudJ F Bach
Jun 17, 1999·Nature Medicine·M A Atkinson, E H Leiter
Sep 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wen YangTerry L Delovitch
Dec 2, 2004·Nature Reviews. Immunology·Bart O RoepMatthias von Herrath
Mar 18, 2005·Annual Review of Immunology·Mark S Anderson, Jeffrey A Bluestone
Aug 10, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jian WangTasuku Honjo
Apr 12, 2006·The Journal of Experimental Medicine·Mary E KeirArlene H Sharpe
Nov 23, 2006·The Journal of Experimental Medicine·Brian T FifeJeffrey A Bluestone
Dec 11, 2008·Journal of Visualized Experiments : JoVE·Kym R Garrod, Michael D Cahalan
Jan 9, 2009·Clinical and Experimental Immunology·A WillcoxN G Morgan
May 19, 2010·Expert Review of Clinical Immunology·Peter J BugelskiEsther Bouman-Thio
Aug 4, 2010·The Journal of Experimental Medicine·Yenkel Grinberg-BleyerEliane Piaggio
Jan 21, 2011·Physiological Reviews·Tom L van BelleMatthias G von Herrath
Jul 9, 2011·Nature Immunology·E John Wherry
Feb 3, 2012·The New England Journal of Medicine·Johnny LudvigssonSabine Baron
Mar 17, 2012·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Y MiyaharaS M Stepkowski
Jun 23, 2012·Diabetes·S Alice LongUNKNOWN Diabetes TrialNet and the Immune Tolerance Network
Jan 26, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Wenhao ChenLawrence Chan
Mar 26, 2013·Nature Reviews. Immunology·Kevan C HeroldJeffrey A Bluestone
Oct 11, 2014·Cell·Felicia W PagliucaDouglas A Melton

❮ Previous
Next ❯

Citations

Nov 8, 2015·Progress in Lipid Research·Laurence Balas, Thierry Durand
Apr 3, 2020·The Journal of Clinical Endocrinology and Metabolism·Xia LiZhiguang Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Qing LiHugh O McDevitt
Proceedings of the National Academy of Sciences of the United States of America
Rachael D AubertRafi Ahmed
© 2021 Meta ULC. All rights reserved